Bharat Enters Chikungunya Fray As Vaccine Moves Into Trials
Executive Summary
Indian vaccine developer Bharat Biotech has moved a candidate vaccine for chikungunya into Phase I trials, joining over a dozen firms worldwide hoping to commercialize the first vaccine to halt transmission of the painful mosquito-borne illness, which is spreading globally.
You may also be interested in...
Bharat, UW-Madison, FluGen Pursue Intranasal COVID-19 Vaccine
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.
Kite’s CAR-T Therapy Makes It Back Onto EMA’s PRIME, Along With Three New Products
The four latest products to be accepted onto the European Medicines Agency’s popular priority medicines scheme target mantle cell lymphoma, chikungunya, hematopoietic stem cell transplant patients, and the rare monogenic disease, X-linked myotubular myopathy.
Themis Bioscience Reaps Bill Gates' Backed CEPI Funding For Lassa Fever And MERS Vaccines
Plans to have candidate vaccines ready for testing against infectious diseases during an evolving epidemic have taken a step forward with the announcement of a partnership between CEPI, the global fund supported by governments and philanthropists, and the vaccine-focused European biotech, Themis Bioscience.